J. W. Vardiman, The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms, Chemico-Biological Interactions, vol.184, issue.1-2, pp.16-20, 2010.
DOI : 10.1016/j.cbi.2009.10.009

J. W. Vardiman, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.
DOI : 10.1182/blood-2009-03-209262

E. Padron, An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies, Blood Cancer Journal, vol.6, issue.7, p.333, 2015.
DOI : 10.1073/pnas.1422050112

K. J. Phekoo, M. A. Richards, H. Møller, and S. A. Schey, & South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England, Haematologica, vol.91, pp.1400-1404, 2006.

G. Osca-gelis, Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain, Haematologica, vol.98, issue.8, pp.95-97, 2013.
DOI : 10.3324/haematol.2013.084061

J. M. Bennett, The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French - American - British Cooperative Leukaemia Group, British Journal of Haematology, vol.71, issue.4, pp.746-754, 1994.
DOI : 10.1016/0145-2126(79)90007-9

D. Selimoglu-buet and E. Solary, Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice, Current Hematologic Malignancy Reports, vol.52, issue.19, pp.301-310, 2014.
DOI : 10.1007/s11899-014-0225-2

J. M. Bennett, World Health Organization classification of the acute leukemias and myelodysplastic syndrome, Int. J. Hematol, vol.72, pp.131-133, 2000.

S. A. Parikh and A. Tefferi, Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.90, issue.11, pp.967-974, 2013.
DOI : 10.1002/ajh.23574

D. Selimoglu-buet, Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood, vol.125, issue.23, pp.3618-3626, 2015.
DOI : 10.1182/blood-2015-01-620781

L. Ziegler-heitbrock, Nomenclature of monocytes and dendritic cells in blood, Blood, vol.116, issue.16, pp.74-80, 2010.
DOI : 10.1182/blood-2010-02-258558

URL : https://hal.archives-ouvertes.fr/hal-00611173

E. A. Wassie, Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study, American Journal of Hematology, vol.31, issue.12, pp.1111-1115, 2014.
DOI : 10.1038/leu.2014.125

E. Such, Cytogenetic risk stratification in chronic myelomonocytic leukemia, Haematologica, vol.96, issue.3, pp.375-383, 2011.
DOI : 10.3324/haematol.2010.030957

R. Itzykson, Clonal architecture of chronic myelomonocytic leukemias, Blood, vol.121, issue.12, pp.2186-2198, 2013.
DOI : 10.1182/blood-2012-06-440347

URL : https://hal.archives-ouvertes.fr/hal-00923316

R. Itzykson and E. Solary, An evolutionary perspective on chronic myelomonocytic leukemia, Leukemia, vol.120, issue.7, pp.1441-1450, 2013.
DOI : 10.1038/nature09367

J. Bastie, R. Aucagne, N. Droin, E. Solary, and L. Delva, Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations, Cellular and Molecular Life Sciences, vol.88, issue.Suppl 3, pp.2853-2861, 2012.
DOI : 10.1007/s00018-012-0956-y

K. Yoshida, Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-69, 2011.
DOI : 10.1038/nature10496

R. Itzykson, Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia, Journal of Clinical Oncology, vol.31, issue.19, pp.2428-2436, 2013.
DOI : 10.1200/JCO.2012.47.3314

R. Aucagne, N. Droin, E. Solary, J. Bastie, and L. Delva, TIF1?: a tumor suppressor gene in chronic myelomonocytic leukemia, Med Sci, vol.27, pp.696-698, 2011.

R. Aucagne, Transcription intermediary factor 1?? is a tumor suppressor in mouse and human chronic myelomonocytic leukemia, Journal of Clinical Investigation, vol.121, issue.6, pp.2361-2370, 2011.
DOI : 10.1172/JCI45213DS1

E. Padron, R. Komrokji, and A. List, The clinical management of chronic myelomonocytic leukemia, Clin Adv Hematol Oncol, vol.12, pp.172-178, 2014.

R. Itzykson, R. Itzkson, P. Fenaux, and E. Solary, Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.387-400, 2013.
DOI : 10.1016/j.beha.2013.09.006

P. Greenberg, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-2088, 1997.

P. L. Greenberg, Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012.
DOI : 10.1182/blood-2012-03-420489

M. M. Patnaik, Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia, vol.7, issue.7, pp.1504-1510, 2013.
DOI : 10.1186/1756-8722-5-12

E. Such, Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia, Blood, vol.121, issue.15, pp.3005-3015, 2013.
DOI : 10.1182/blood-2012-08-452938

M. M. Patnaik, ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia, vol.28, issue.11, pp.2206-2212, 2014.
DOI : 10.1038/leu.2013.286

E. Wattel, A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group, Blood, vol.88, pp.2480-2487, 1996.

T. Braun, Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial, Blood, vol.118, issue.14, pp.3824-3831, 2011.
DOI : 10.1182/blood-2011-05-352039

K. Meldi, Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia, Journal of Clinical Investigation, vol.125, issue.5, pp.1857-1872, 2015.
DOI : 10.1172/JCI78752DS1

K. Ghoshal, 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal, Molecular and Cellular Biology, vol.25, issue.11
DOI : 10.1128/MCB.25.11.4727-4741.2005

K. Patel, Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme, Nucleic Acids Research, vol.38, issue.13, pp.4313-4324, 2010.
DOI : 10.1093/nar/gkq187

E. A. Griffiths and S. D. Gore, DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes, Seminars in Hematology, vol.45, issue.1, pp.23-30, 2008.
DOI : 10.1053/j.seminhematol.2007.11.007

Z. C. Han, Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents, Blood, vol.89, pp.2328-2335, 1997.

S. K. Gupta and J. P. Singh, Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression, The Journal of Cell Biology, vol.127, issue.4, pp.1121-1127, 1994.
DOI : 10.1083/jcb.127.4.1121

F. Onida, Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups, Haematologica, vol.98, issue.9, pp.1344-1352, 2013.
DOI : 10.3324/haematol.2013.084020

H. Eissa, Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities, Biology of Blood and Marrow Transplantation, vol.17, issue.6, pp.908-915, 2011.
DOI : 10.1016/j.bbmt.2010.09.018

S. Park, Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire, European Journal of Haematology, vol.151, issue.5, pp.355-364, 2013.
DOI : 10.1111/ejh.12073

H. Cheng, V. G. Kirtani, and U. Gergis, Current status of allogeneic HST for chronic myelomonocytic leukemia, Bone Marrow Transplantation, vol.112, issue.4, pp.535-541, 2012.
DOI : 10.1038/bmt.2011.141

E. J. Feldman, On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia, Leukemia, vol.7, issue.9, pp.1707-1711, 2008.
DOI : 10.1158/1078-0432.CCR-07-1532

M. T. Voso, Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes, Clinical Cancer Research, vol.15, issue.15, pp.5002-5007, 2009.
DOI : 10.1158/1078-0432.CCR-09-0494

G. Kong, Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm, Journal of Clinical Investigation, vol.124, issue.6, pp.2762-2773, 2014.
DOI : 10.1172/JCI74182DS1

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038579

L. Bachegowda, Signal transduction inhibitors in treatment of myelodysplastic syndromes, Journal of Hematology & Oncology, vol.6, issue.1, p.50, 2013.
DOI : 10.1080/10428190410001723322

N. Kotecha, Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates, Cancer Cell, vol.14, issue.4, pp.335-343, 2008.
DOI : 10.1016/j.ccr.2008.08.014

M. R. Savona, An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults, Blood, vol.125, issue.12, pp.1857-1865, 2015.
DOI : 10.1182/blood-2014-10-607341

R. Yang, CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells, Cancer Research, vol.66, issue.13, pp.6807-6815, 2006.
DOI : 10.1158/0008-5472.CAN-05-3755

I. Dufait, <em>Ex vivo</em> generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer, Oncotarget, vol.6, issue.14, pp.12369-12382, 2015.
DOI : 10.18632/oncotarget.3682

S. Kusmartsev and D. I. Gabrilovich, Immature myeloid cells and cancer-associated immune suppression, Cancer Immunology, Immunotherapy, vol.51, issue.6, pp.293-298, 2002.
DOI : 10.1007/s00262-002-0280-8

D. I. Gabrilovich and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system, Nature Reviews Immunology, vol.172, issue.3, pp.162-174, 2009.
DOI : 10.1038/nri2506

I. M. Stromnes, Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity, Gut, vol.6, issue.11, pp.1769-1781, 2014.
DOI : 10.1136/gutjnl-2013-306271

F. Zhao, Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma, Immunology, vol.123, issue.1, pp.141-149, 2009.
DOI : 10.1111/j.1365-2567.2009.03105.x

A. H. Zea, Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion, Cancer Res, vol.65, pp.3044-3048, 2005.

P. C. Rodriguez, Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes, Cancer Research, vol.69, issue.4, pp.1553-1560, 2009.
DOI : 10.1158/0008-5472.CAN-08-1921

L. A. Haile, Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway, Gastroenterology, vol.135, issue.3, pp.871-881, 2008.
DOI : 10.1053/j.gastro.2008.06.032

L. Christiansson, Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia, PLoS ONE, vol.90, issue.4, p.55818, 2013.
DOI : 10.1371/journal.pone.0055818.s007

D. Veirman and K. , Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells, Oncotarget, vol.6, issue.12, pp.10532-10547, 2015.
DOI : 10.18632/oncotarget.3300

G. T. Gorgun, Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans, Blood, vol.121, issue.15, pp.2975-2987, 2013.
DOI : 10.1182/blood-2012-08-448548

N. Umemura, Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics, Journal of Leukocyte Biology, vol.83, issue.5, pp.1136-1144, 2008.
DOI : 10.1189/jlb.0907611

S. Brandau, K. Moses, and S. Lang, The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins?, Seminars in Cancer Biology, vol.23, issue.3
DOI : 10.1016/j.semcancer.2013.02.007

D. I. Gabrilovich, S. Ostrand-rosenberg, and V. Bronte, Coordinated regulation of myeloid cells by tumours, Nature Reviews Immunology, vol.205, issue.4, pp.253-268, 2012.
DOI : 10.1038/nri3175

K. Movahedi, Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity, Blood, vol.111, issue.8, pp.4233-4244, 2008.
DOI : 10.1182/blood-2007-07-099226

Y. Nefedova, Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer, The Journal of Immunology, vol.172, issue.1, pp.464-474, 2004.
DOI : 10.4049/jimmunol.172.1.464

P. C. Rodríguez and A. C. Ochoa, Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives, Immunological Reviews, vol.63, issue.3, pp.180-191, 2008.
DOI : 10.1084/jem.20061104

N. Droin, Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia, Blood, vol.115, issue.1, pp.78-88, 2010.
DOI : 10.1182/blood-2009-05-224352

R. Mashima, Y. Hishida, T. Tezuka, and Y. Yamanashi, The roles of Dok family adapters in immunoreceptor signaling, Immunological Reviews, vol.191, issue.1, pp.273-285, 2009.
DOI : 10.1111/j.1600-065X.2009.00844.x

S. Lemay, D. Davidson, S. Latour, and A. Veillette, Dok-3, a Novel Adapter Molecule Involved in the Negative Regulation of Immunoreceptor Signaling, Molecular and Cellular Biology, vol.20, issue.8, pp.2743-2754, 2000.
DOI : 10.1128/MCB.20.8.2743-2754.2000

J. Grimm, Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation, The Journal of Cell Biology, vol.14, issue.2, pp.345-354, 2001.
DOI : 10.1083/jcb.200102032

R. J. Crowder, H. Enomoto, M. Yang, E. M. Johnson, and J. Milbrandt, Dok-6, a Novel p62 Dok Family Member, Promotes Ret-mediated Neurite Outgrowth, Journal of Biological Chemistry, vol.279, issue.40
DOI : 10.1074/jbc.M403726200

K. Okada, The Muscle Protein Dok-7 Is Essential for Neuromuscular Synaptogenesis, Science, vol.312, issue.5781, pp.1802-1805, 2006.
DOI : 10.1126/science.1127142

Y. Yamanashi, Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling, Genes Dev, vol.14, pp.11-16, 2000.

M. Niki, Role of Dok-1 and Dok-2 in Leukemia Suppression, The Journal of Experimental Medicine, vol.95, issue.12, pp.1689-1695, 2004.
DOI : 10.1038/sj.onc.1201005

T. Yasuda, Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia, The Journal of Experimental Medicine, vol.95, issue.12, pp.1681-1687, 2004.
DOI : 10.1038/sj.onc.1206620

T. Yasuda, Dok-1 and Dok-2 are negative regulators of T cell receptor signaling, International Immunology, vol.19, issue.4, pp.487-495, 2007.
DOI : 10.1093/intimm/dxm015

A. H. Berger, Identification of DOK genes as lung tumor suppressors, Nature Genetics, vol.121, issue.3, pp.216-223, 2010.
DOI : 10.1038/ng.527

R. Mashima, Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma, Laboratory Investigation, vol.61, issue.9, pp.1357-1364, 2010.
DOI : 10.1016/j.ccr.2006.03.028

H. Miyagaki, DOK2 as a Marker of Poor Prognosis of Patients with Gastric Adenocarcinoma After Curative Resection, Annals of Surgical Oncology, vol.49, issue.5, pp.1560-1567, 2012.
DOI : 10.1245/s10434-011-2157-6

C. Quivoron, TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is??a Recurrent Event during Human Lymphomagenesis, Cancer Cell, vol.20, issue.1, pp.25-38, 2011.
DOI : 10.1016/j.ccr.2011.06.003

A. Saulnier, Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers, International Journal of Cancer, vol.32, issue.11, pp.2484-2494, 2012.
DOI : 10.1002/ijc.26299

URL : https://hal.archives-ouvertes.fr/hal-01262953

S. Lee, Dok1 expression and mutation in Burkitt's lymphoma cell lines, Cancer Letters, vol.245, issue.1-2, pp.44-50, 2007.
DOI : 10.1016/j.canlet.2005.10.045

S. Lee, Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia, Oncogene, vol.23, issue.13, pp.2287-2297, 2004.
DOI : 10.1038/sj.onc.1207385

N. Cervera, Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia, American Journal of Hematology, vol.116, issue.6, pp.604-609, 2014.
DOI : 10.1002/ajh.23702

E. Schuler, Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias, Leukemia Research, vol.38, issue.12, pp.1413-1419, 2014.
DOI : 10.1016/j.leukres.2014.09.003

E. Chung, C. Hsu, and M. Kondo, Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder, PLoS ONE, vol.21, issue.12, p.28350, 2011.
DOI : 10.1371/journal.pone.0028350.s003

S. L. Abrams, The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy, Cell Cycle, vol.8, issue.9, pp.1781-1791, 2010.
DOI : 10.4161/cc.9.9.11483

L. S. Steelman, Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs, Cell Cycle, vol.8, issue.8, pp.1629-1638, 2010.
DOI : 10.4161/cc.9.8.11487

C. Ricci, RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant, Clinical Cancer Research, vol.16, issue.8, pp.2246-2256, 2010.
DOI : 10.1158/1078-0432.CCR-09-2112

C. M. Diaz-montero, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin???cyclophosphamide chemotherapy, Cancer Immunology, Immunotherapy, vol.65, issue.1, pp.49-59, 2009.
DOI : 10.1007/s00262-008-0523-4

H. Huang, G. Zhang, G. Li, H. Ma, and X. Zhang, Circulating CD14+HLA-DR???/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC, Tumor Biology, vol.366, issue.8, pp.10-1007, 2015.
DOI : 10.1007/s13277-015-3426-y

A. Huang, Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunology, Immunotherapy, vol.119, issue.24, pp.1439-1451, 2013.
DOI : 10.1007/s00262-013-1450-6

Y. Cao, BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity, Cancer Research, vol.74, issue.18, pp.5091-5102, 2014.
DOI : 10.1158/0008-5472.CAN-13-3171

J. Liu, Y. Zhou, Q. Huang, and L. Qiu, CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia, Oncol Lett, vol.9, pp.1167-1172, 2015.

B. Samra and E. , New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients, British Journal of Haematology, vol.113, issue.3, pp.347-356, 2012.
DOI : 10.1111/j.1365-2141.2012.09069.x

URL : https://hal.archives-ouvertes.fr/inserm-00681007

L. Malcovati, Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia, Blood, vol.124, issue.9, pp.1513-1521, 2014.
DOI : 10.1182/blood-2014-03-560227

M. E. Figueroa, MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood, vol.114, issue.16, pp.3448-3458, 2009.
DOI : 10.1182/blood-2009-01-200519

A. P. Feinberg and B. Tycko, The history of cancer epigenetics, Nature Reviews Cancer, vol.74, issue.2, pp.143-153, 2004.
DOI : 10.1038/nrc1279

P. A. Jones and S. B. Baylin, The fundamental role of epigenetic events in cancer, Nat. Rev. Genet, vol.3, pp.415-428, 2002.

E. Padron, GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia, Blood, vol.121, issue.25, pp.5068-5077, 2013.
DOI : 10.1182/blood-2012-10-460170

M. G. Lechner, D. J. Liebertz, and A. L. Epstein, Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells, The Journal of Immunology, vol.185, issue.4, pp.2273-2284, 2010.
DOI : 10.4049/jimmunol.1000901

R. Z. Panni, Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer, Cancer Immunology, Immunotherapy, vol.21, issue.Suppl 2, pp.513-528, 2014.
DOI : 10.1007/s00262-014-1527-x